文献速递中枢神经肿瘤放疗

65-69岁与≥70岁新诊断胶质母细胞瘤患者预后对比:倾向性评分匹配分析

The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing.
PubMed 文献 · Radiother Oncol · 2020-11-25

结果显示两组无进展生存和总生存均无显著差异,提示年龄分层不宜仅以65岁或70岁为界。

要点

  • 65-69岁组接受60 Gy/30次放疗,≥70岁组接受40.5 Gy/15次,两组生存无显著差异。
  • 匹配后65-69岁组中位PFS 10个月,≥70岁组9个月(p=0.530)。
  • 匹配后65-69岁组中位OS 14个月,≥70岁组12个月(p=0.357)。

核心结论

  • 倾向性评分匹配分析显示65-69岁与≥70岁新诊断胶质母细胞瘤患者预后相似。
  • 尽管65-69岁组接受了更繁重的放疗方案,其生存结局与≥70岁组无显著差异。
  • 对于较年轻的老年(65-69岁)新诊断胶质母细胞瘤患者,也应考虑大分割放疗。

研究设计与样本

  • 所有患者接受手术后继以放疗联合同步及辅助替莫唑胺化疗。
  • 放疗剂量:65-69岁患者为60 Gy/30次,≥70岁患者为40.5 Gy/15次。
  • 经1:1倾向性评分匹配后每组86例,协变量分布均衡。

主要发现

  • 匹配后65-69岁组中位PFS 10个月,1、2、3年PFS率分别为33.3%、13.1%、6.6%;≥70岁组中位PFS 9个月,1、2、3年PFS率分别为34.7%、11%、4.8%(p=0.530)。
  • 匹配后65-69岁组中位OS 14个月,1、2、3年OS率分别为54.1%、23.4%、13.9%;≥70岁组中位OS 12个月,1、2、3年OS率分别为49.3%、21.5%、10%(p=0.357)。
  • 不同年龄组间未记录到差异。

临床怎么用

  • 对于65-69岁新诊断胶质母细胞瘤患者,可考虑采用大分割放疗方案。
  • 年龄分层定义老年患者时,65岁与70岁界限的临床意义需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard of care for elderly, newly-diagnosed glioblastoma patients consists, if feasible, of surgical resection followed by a short course of radiation therapy (RT) with concomitant and adjuvant temozolomide chemotherapy (TMZCHT). To date, the literature lacks of consistence in the definition of elderly, if older than 65 years, or 70 years. Aim of this study was to explore whether differences exist between these two cohorts, comparing outcomes using a propensity score matched analysis (PSM). MATERIALS AND METHODS: Two hundred twenty-one elderly newly diagnosed glioblastoma patients were included. All patients received surgery followed by RT with concurrent and adjuvant TMZCHT. The RT dose prescribed was 60 Gy/30 fractions for patients 65-69-year-old or 40.5 Gy/15 fractions for ≥70-year-old. After 1:1 matching there were 86 patients in each group. Distribution of covariates was adequately balanced in the matched data set. RESULTS: After PSM median PFS time, 1,2,3-year PFS rates were 10 months, 33.3%, 13.1%, and 6.6% for the 65-69-year group, 9 months, 34.7%, 11% and 4.8% for the ≥70-year group (p = 0.530). Median OS time, and 1,2,3-year OS rates were 14 months, 54.1%, 23.4%, 13.9% for the 65-69-year old group, and 12 months, 49.3%, 21.5%, 10% for the ≥70-year group (p = 0.357). No differences were recorded in relation to different groups of age. CONCLUSIONS: The PSM analyses showed a similar outcome in 65-69-year old patients compared to older ones notwithstanding a more burdensome RT schedule. Hypofractionated RT treatment has to be considered also in this group of younger elderly, newly-diagnosed GBM patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Navarria P, Pessina F, Franzese C, et al. The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. Radiother Oncol. 2020. PMID: 33245946. doi:10.1016/j.radonc.2020.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。